Insulin-like growth factors in endometrioid adenocarcinoma: Correlation with clinico-pathological features and estrogen receptor expression

BMC Cancer

Volumn 12, Issue , 2012, Pages

  Liang, Yuan Jiao ^a   Hao, Qun ^a   Zhang, Hui Ming ^a   Wu, Yuan Zhe ^a   Wang, Jian Dong ^a  

^a MEDICAL SCHOOL OF NANJING UNIVERSITY   (China)

Author keywords

Endometrioid adenocarcinoma; Estrogen receptor; Insulin like growth factor

Indexed keywords

ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; MESSENGER RNA; SOMATOMEDIN B; SOMATOMEDIN B RECEPTOR; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C; SOMATOMEDIN C RECEPTOR;

ADULT; AGED; ARTICLE; CANCER INVASION; CANCER STAGING; CANCER TISSUE; CARCINOGENESIS; CONTROLLED STUDY; DISEASE ASSOCIATION; ENDOMETRIOID CARCINOMA; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; NUCLEOTIDE SEQUENCE; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; RETROSPECTIVE STUDY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ADULT; AGED; ANALYSIS OF VARIANCE; CARCINOMA, ENDOMETRIOID; CASE-CONTROL STUDIES; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTORS, ESTROGEN; RETROSPECTIVE STUDIES; RNA, MESSENGER; SOMATOMEDINS;

EID: 84862487921     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-12-262     Document Type: Article

References (31)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010, 60(5):277-300. 10.3322/caac.20073, 20610543.
2. Creasman WT, Odicino F, Maisonneuve P, Quinn MA, Beller U, Benedet JL, Heintz AP, Ngan HY, Pecorelli S. Carcinoma of the corpus uteri. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer. Int J Gynaecol Obstet 2006, 95(Suppl 1):S105-S143.
3. Akhmedkhanov A, Zeleniuch-Jacquotte A, Toniolo P. Role of exogenous and endogenous hormones in endometrial cancer: review of the evidence and research perspectives. Ann N Y Acad Sci 2001, 943:296-315.
4. Cooke PS, Buchanan DL, Young P, Setiawan T, Brody J, Korach KS, Taylor J, Lubahn DB, Cunha GR. Stromal estrogen receptors mediate mitogenic effects of estradiol on uterine epithelium. Proc Natl Acad Sci USA 1997, 94(12):6535-6540. 10.1073/pnas.94.12.6535, 21085, 9177253.
5. Chambers JT, MacLusky N, Eisenfield A, Kohorn EI, Lawrence R, Schwartz PE. Estrogen and progestin receptor levels as prognosticators for survival in endometrial cancer. Gynecol Oncol 1988, 31(1):65-81. 10.1016/0090-8258(88)90270-3, 3410357.
6. Pertschuk LP, Masood S, Simone J, Feldman JG, Fruchter RG, Axiotis CA, Greene GL. Estrogen receptor immunocytochemistry in endometrial carcinoma: a prognostic marker for survival. Gynecol Oncol 1996, 63(1):28-33. 10.1006/gyno.1996.0273, 8898164.
7. Creasman WT. Prognostic significance of hormone receptors in endometrial cancer. Cancer 1993, 71(4 Suppl):1467-1470.
8. Chakravarty D, Srinivasan R, Ghosh S, Gopalan S, Rajwanshi A, Majumdar S. Estrogen receptor beta1 and the beta2/betacx isoforms in nonneoplastic endometrium and in endometrioid carcinoma. Int J Gynecol Cancer 2007, 17(4):905-913. 10.1111/j.1525-1438.2006.00851.x, 17309672.
9. Mylonas I. Prognostic significance and clinical importance of estrogen receptor alpha and beta in human endometrioid adenocarcinomas. Oncol Rep 2010, 24(2):385-393.
10. Chakravarty D, Srinivasan R, Ghosh S, Rajwanshi A, Gopalan S. Estrogen receptor beta (ERbeta) in endometrial simple hyperplasia and endometrioid carcinoma. Appl Immunohistochem Mol Morphol 2008, 16(6):535-542. 10.1097/PAI.0b013e31816755a9, 18931615.
11. Reynolds RK, Hu C, Baker VV. Transforming growth factor-alpha and insulin-like growth factor-I, but not epidermal growth factor, elicit autocrine stimulation of mitogenesis in endometrial cancer cell lines. Gynecol Oncol 1998, 70(2):202-209. 10.1006/gyno.1998.5089, 9740691.
12. McCampbell AS, Broaddus RR, Loose DS, Davies PJ. Overexpression of the insulin-like growth factor I receptor and activation of the AKT pathway in hyperplastic endometrium. Clin Cancer Res 2006, 12(21):6373-6378. 10.1158/1078-0432.CCR-06-0912, 17085648.
13. Murphy LJ, Ghahary A. Uterine insulin-like growth factor-1: regulation of expression and its role in estrogen-induced uterine proliferation. Endocr Rev 1990, 11(3):443-453. 10.1210/edrv-11-3-443, 2226350.
14. Rutanen EM, Nyman T, Lehtovirta P, Ammala M, Pekonen F. Suppressed expression of insulin-like growth factor binding protein-1 mRNA in the endometrium: a molecular mechanism associating endometrial cancer with its risk factors. Int J Cancer 1994, 59(3):307-312. 10.1002/ijc.2910590303, 7523316.
15. Pavelic J, Radakovic B, Pavelic K. Insulin-like growth factor 2 and its receptors (IGF 1R and IGF 2R/mannose 6-phosphate) in endometrial adenocarcinoma. Gynecol Oncol 2007, 105(3):727-735. 10.1016/j.ygyno.2007.02.012, 17399767.
16. Suvanto-Luukkonen E, Sundstrom H, Penttinen J, Kauppila A, Rutanen EM. Insulin-like growth factor-binding protein-1: a biochemical marker of endometrial response to progestin during hormone replacement therapy. Maturitas 1995, 22(3):255-262. 10.1016/0378-5122(95)00935-E, 8746884.
17. Shabani N, Kuhn C, Kunze S, Schulze S, Mayr D, Dian D, Gingelmaier A, Schindlbeck C, Willgeroth F, Sommer H, et al. Prognostic significance of oestrogen receptor alpha (ERalpha) and beta (ERbeta), progesterone receptor A (PR-A) and B (PR-B) in endometrial carcinomas. Eur J Cancer 2007, 43(16):2434-2444. 10.1016/j.ejca.2007.08.014, 17911007.
18. Pavelic J, Matijevic T, Knezevic J. Biological & physiological aspects of action of insulin-like growth factor peptide family. Indian J Med Res 2007, 125(4):511-522.
19. Lukanova A, Lundin E, Akhmedkhanov A, Micheli A, Rinaldi S, Zeleniuch-Jacquotte A, Lenner P, Muti P, Biessy C, Krogh V, et al. Circulating levels of sex steroid hormones and risk of ovarian cancer. Int J Cancer 2003, 104(5):636-642. 10.1002/ijc.10990, 12594820.
20. Gunter MJ, Hoover DR, Yu H, Wassertheil-Smoller S, Manson JE, Li J, Harris TG, Rohan TE, Xue X, Ho GY, et al. A prospective evaluation of insulin and insulin-like growth factor-I as risk factors for endometrial cancer. Cancer Epidemiol Biomarkers Prev 2008, 17(4):921-929. 10.1158/1055-9965.EPI-07-2686, 3090086, 18398032.
21. Hamelers IH, Steenbergh PH. Interactions between estrogen and insulin-like growth factor signaling pathways in human breast tumor cells. Endocr Relat Cancer 2003, 10(2):331-345. 10.1677/erc.0.0100331, 12790794.
22. Zhu L, Pollard JW. Estradiol-17beta regulates mouse uterine epithelial cell proliferation through insulin-like growth factor 1 signaling. Proc Natl Acad Sci USA 2007, 104(40):15847-15851. 10.1073/pnas.0705749104, 2000402, 17895382.
23. Satyamoorthy K, Li G, Vaidya B, Patel D, Herlyn M. Insulin-like growth factor-1 induces survival and growth of biologically early melanoma cells through both the mitogen-activated protein kinase and beta-catenin pathways. Cancer Res 2001, 61(19):7318-7324.
24. LeRoith D, Roberts CT. The insulin-like growth factor system and cancer. Cancer Lett 2003, 195(2):127-137. 10.1016/S0304-3835(03)00159-9, 12767520.
25. Larsson O, Girnita A, Girnita L. Role of insulin-like growth factor 1 receptor signalling in cancer. Br J Cancer 2005, 92(12):2097-2101. 10.1038/sj.bjc.6602627, 2361813, 15956962.
26. Oka Y, Waterland RA, Killian JK, Nolan CM, Jang HS, Tohara K, Sakaguchi S, Yao T, Iwashita A, Yata Y, et al. M6P/IGF2R tumor suppressor gene mutated in hepatocellular carcinomas in Japan. Hepatology 2002, 35(5):1153-1163. 10.1053/jhep.2002.32669, 11981765.
27. Jamieson TA, Brizel DM, Killian JK, Oka Y, Jang HS, Fu X, Clough RW, Vollmer RT, Anscher MS, Jirtle RL. M6P/IGF2R loss of heterozygosity in head and neck cancer associated with poor patient prognosis. BMC Cancer 2003, 3:4. 10.1186/1471-2407-3-4, 151601, 12589712.
28. Kashima H, Shiozawa T, Miyamoto T, Suzuki A, Uchikawa J, Kurai M, Konishi I. Autocrine stimulation of IGF1 in estrogen-induced growth of endometrial carcinoma cells: involvement of the mitogen-activated protein kinase pathway followed by up-regulation of cyclin D1 and cyclin E. Endocr Relat Cancer 2009, 16(1):113-122.
29. Billiard J, Grewal SS, Lukaesko L, Stork PJ, Rotwein P. Hormonal control of insulin-like growth factor I gene transcription in human osteoblasts: dual actions of cAMP-dependent protein kinase on CCAAT/enhancer-binding protein delta. J Biol Chem 2001, 276(33):31238-31246. 10.1074/jbc.M103634200, 11390399.
30. Lacey JV, Potischman N, Madigan MP, Berman ML, Mortel R, Twiggs LB, Barrett RJ, Wilbanks GD, Lurain JR, Fillmore CM, et al. Insulin-like growth factors, insulin-like growth factor-binding proteins, and endometrial cancer in postmenopausal women: results from a U.S. case-control study. Cancer Epidemiol Biomarkers Prev 2004, 13(4):607-612.
31. McGrath M, Lee IM, Buring J, De Vivo I. Common genetic variation within IGFI, IGFII, IGFBP-1, and IGFBP-3 and endometrial cancer risk. Gynecol Oncol 2011, 120(2):174-178. 10.1016/j.ygyno.2010.10.012, 3238452, 21078522.